Investors | Resources
Investor resources
Reports, meeting documents, prospectuses, scientific publications and a glossary of the terms we use. Presentations and webinars have their own page.
Reports and results
30 Sep 2026Half-year report 2026Six months to 30 June 2026RNS
29 Apr 2026Annual Report and Accounts 2025Year to 31 December 2025 (Companies House filing)PDF
30 Sep 2025Half-year report 2025Six months to 30 June 2025PDF
16 Apr 2025Annual Report and Accounts 2024Year to 31 December 2024 (Companies House filing)PDF
13 Sep 2024Half-year report 2024Six months to 30 June 2024RNS
30 Apr 2024Annual Report and Accounts 2023Year to 31 December 2023 (Companies House filing)PDF
27 Sep 2023Half-year report 2023Six months to 30 June 2023RNS
27 Apr 2023Annual Report and Accounts 2022Year to 31 December 2022 (Companies House filing)PDF
30 Sep 2022Half-year report 2022Six months to 30 June 2022RNS
29 Jun 2022Annual Report and Accounts 2021Seven months to 31 December 2021 (Companies House filing)PDF
General meetings
Notices of meeting, proxy forms and results of voting.
Annual General Meeting 2026Notice of meeting · 27 May 2026Results of voting · 19 Jun 2026Notice (PDF)Proxy form (PDF)
Annual General Meeting 2025Notice of meeting · 3 Jun 2025Results of voting · 27 Jun 2025Notice (PDF)Proxy form (PDF)
General Meeting, April 2025Circular and notice of meeting · 10 Apr 2025Results of voting · 28 Apr 2025Circular and notice (PDF)Proxy form (PDF)
General Meeting, January 2025 (change of name)Held as Graft Polymer (UK) plc, the Company’s former nameNotice of meeting · 3 Dec 2024Results of voting · 6 Jan 2025
Annual General Meeting 2024Held as Graft Polymer (UK) plc, the Company’s former nameNotice of meeting · 4 Jun 2024Results of voting · 28 Jun 2024Notice (PDF)
General Meeting, January 2024Held as Graft Polymer (UK) plc, the Company’s former nameNotice of meeting · 27 Dec 2023Results of voting · 8 Jan 2024Notice (PDF)Proxy form (PDF)
Annual General Meeting 2023Held as Graft Polymer (UK) plc, the Company’s former nameNotice of meeting · 4 Jul 2023Results of voting · 27 Jul 2023Notice (PDF)Proxy form (PDF)
Annual General Meeting 2022Held as Graft Polymer (UK) plc, the Company’s former nameNotice of meeting · 4 Jul 2022Results of voting · 28 Jul 2022Notice (PDF)
Other documents
Scientific publications
The evidence behind our programmes
SVN-001 | Phase 2a/b trial
Grabski M, McAndrew A, Lawn W, et al. “Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.” Am J Psychiatry. 2022;179(2):152–162. doi:10.1176/appi.ajp.2021.21030277
SVN-001 | Post hoc analysis (preprint)
Morgan CJA, Nutt DJ. “No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE Trial.” medRxiv. Posted 28 September 2026. doi:10.64898/2026.09.26.26363761. Not peer-reviewed.
SVN-001 | Mechanism
Das RK, et al. “Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories.” Nat Commun. 2019;10:5187. doi:10.1038/s41467-019-13162-w
SVN-002 | Esketamine in problem drinkers
Gent EM, et al. “Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.” J Psychopharmacol. 2024;38(6):541–550. doi:10.1177/02698811241254834
SVN-002 | Esketamine OTF pharmacokinetics
Simons P, et al. “S-Ketamine Oral Thin Film—Part 1: Population Pharmacokinetics…” Front Pain Res. 2022;3:946486. doi:10.3389/fpain.2022.946486
SVN-002 | Psychedelic-type experience
Rothberg RL, et al. “Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking…” J Psychopharmacol. 2021;35(2):150–158.
Author disclosures (Morgan and Nutt preprint): D. Nutt is Chief Scientific Officer of, and a shareholder in, Solvonis Therapeutics. C. Morgan receives arms-length funding from Solvonis Therapeutics for the NIHR-funded MORE-KARE trial and has consulted for Solvonis Therapeutics and Eli Lilly. Third-party information has not been independently verified by the Company. Preprints are not peer-reviewed. Full references for each programme are on its page.
Glossary
The terms we use
505(b)(2)
An FDA pathway that can draw on data for an already-approved drug.
Alcohol use disorder (AUD)
A medical condition characterised by an impaired ability to stop or control alcohol use. SVN-001 is developed for severe AUD; SVN-002 for moderate-to-severe AUD.
Anhedonia
The loss of pleasure and motivation; a core symptom of major depressive disorder.
ATDP
NIDA’s Addiction Treatment Discovery Program, which funds and conducts early preclinical evaluation for methamphetamine and cocaine addiction.
Composition-of-matter patent
A patent that claims the compound itself.
DAT
The dopamine transporter.
De novo
Newly designed molecules (new chemical entities), as opposed to existing medicines.
EMA
The European Medicines Agency.
Enantiomer
One of two mirror-image forms of a molecule. Ketamine is a 50:50 mixture of R-ketamine and S-ketamine (esketamine).
Entactogen
A class of psychoactive compound, of which MDMA is the best-known example.
EU4
France, Germany, Italy and Spain.
Heavy drinking day
In the SVN-001 Phase 3, a day with more than 60 g of alcohol for men or 40 g for women (EMA thresholds). Earlier analyses used different thresholds.
ILAP
The MHRA’s Innovative Licensing and Access Pathway. SVN-001 holds an Innovation Passport.
IND
Investigational New Drug application, submitted to the FDA before clinical trials in the U.S.
Major depressive disorder (MDD)
A mood disorder; anhedonia is a core symptom.
MHRA
The UK Medicines and Healthcare products Regulatory Agency.
MoU
Memorandum of understanding.
Mystical-experience score
The standard measure of the psychedelic experience in psilocybin and LSD research (0–150 in the SVN-002 data).
NCE
New chemical entity.
NIDA, NIHR, MRC
The U.S. National Institute on Drug Abuse; the National Institute for Health and Care Research; the Medical Research Council.
OTF
Oral thin film. SVN-002 is an esketamine oral thin film.
Post hoc analysis
An analysis that was not specified in advance and is run after the data are seen. Its results are treated as exploratory.
PTSD
Post-traumatic stress disorder.
RNS
An announcement made through a Regulatory Information Service. RNS announcements prevail over this website.
Stimulant use disorder (StUD)
Addiction to stimulants such as cocaine and methamphetamine.
Treatment-resistant depression (TRD)
Depression that has not responded adequately to treatment. The SVN-002 market comparison uses a U.S. estimate of TRD prevalence.
Value-added medicine
A differentiated treatment built on established pharmacology, clinical experience and regulatory precedent.